The Lancet Diabetes & Endocrinology, dedicated to covering the disciplines of diabetes, endocrinology, and metabolism, is the latest title in The Lancet family of specialty journals. Continuing in ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, offering a new treatment option for cardiovascular protection. Sotagliflozin, a re ...

Sotagliflozin, recently approved by the FDA for treating type 2 diabetes and kidney disease in patients with cardiovascular ...

Lancets play an integral part in glucose monitoring for diabetes management as single-use designs help ensure safety and hygiene thereby decreasing risks of infections or cross-contamination ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

While conducting the study, the researchers tracked data from more than 10,000 patients who presented with type 2 diabetes, ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns ...

Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...

About a quarter of the 828 million adults globally living with diabetes — either type 1 or 2 — are in India, a paper published in The Lancet said on Wednesday. Apart from the 212 million ...